论文部分内容阅读
目的对比格列美脲与格列齐特两种药物治疗2型糖尿病的临床疗效。方法选取2014年10月至2016年9月我院收治的2型糖尿病患者194例,随机分为观察组与对照组,观察组患者采用格列美脲治疗,对照组患者采用格列齐特治疗,对比两组患者生化指标与并发症。结果观察组患者治疗后空腹血糖(FPG)、餐后2h(2hPG)血糖、糖化血红蛋白(HbA1c)空腹胰岛素(FINS)与对照组相比明显较低(P<0.05);对照组患者治疗后FINS加重但与治疗前相比差异不显著(P>0.05);观察组患者并发症发生率2.06%与对照组相比5.15%无显著性差异(P>0.05)。结论格列美脲治疗2型糖尿病效果更显著,且并发症较少。
Objective To compare the clinical efficacy of glimepiride and gliclazide in the treatment of type 2 diabetes mellitus. Methods A total of 194 type 2 diabetic patients admitted to our hospital from October 2014 to September 2016 were randomly divided into observation group and control group. Patients in observation group were treated with glimepiride, while patients in control group were treated with gliclazide The biochemical indexes and complications of two groups were compared. Results After treatment, fasting blood glucose (FPG), postprandial 2h (2hPG) blood glucose and HbA1c fasting insulin (FINS) were significantly lower in the observation group than those in the control group (P <0.05) (P> 0.05). The incidence of complication in observation group was 2.06% compared with 5.15% in control group (P> 0.05). Conclusion Glimepiride treatment of type 2 diabetes more effective, and fewer complications.